Author

Jingxin Li

Jiangsu Provincial Center for Disease Control and PreventionORCID 0000-0002-7033-5151Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Systems Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Approach:machine learning (classical)· 1 Approach:statistical model· 1

Frequent Co-Authors

Aoife O’FarrelliD· 1 shared Arjun RajiD· 1 shared Chengliang Hu· 1 shared Chunhao YangiD· 1 shared Dan Yang ZhaoiD· 1 shared Enming YuaniD· 1 shared Fang WaniD· 1 shared Fengcai ZhuiD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Aoife O’FarrellORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

AP-1 Mediates Cellular Adaptation and Memory Formation During Therapy Resistance

Jingxin Li, Pavithran T. Ravindran, Aoife O’Farrell, Gianna T. Busch, Ryan H. Boe, Zijian Niu, Sean Woo, Margaret C. Dunagin, Naveen Jain, Yogesh Goyal, Kavitha Sarma, Meenhard Herlyn, Arjun Raj

The paper shows melanoma cells develop therapy resistance through AP-1-mediated cellular memories that encode transient gene expression and chromatin changes.

bioRxiv · Jul 25, 2024 · PreprintSystems Biology

A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19

Yiyue Ge, Tingzhong Tian, Suling Huang, Fang Wan, Jingxin Li, Shuya Li, Xiaoting Wang, Hui Mei Yang, Lixiang Hong, Nian Wu, Enming Yuan, Yunan Luo, Lili Cheng, Chengliang Hu, Yipin Lei, , Jianyang Zeng

This paper presents a data-driven drug repositioning framework that identifies CVL218, a PARP1 inhibitor, as a potential therapeutic for COVID-19 through in silico and experimental validation.

Signal Transduction and Targeted Therapy · Apr 24, 2021Peer-reviewedSystems Biology